Get started
Author

Panagiota Zygoura

Observed name: P. Zygoura
ORCID: 0000-0002-4867-8676
Observed ORCID: 0000-0002-4867-8676
OpenAlex ID: A5022806547
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
2021 · S. Peters, J.-L. Pujol, et al. · Annals of Oncology · 129
PDF
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
2019 · Nathan I. Cherny, Elisabeth G.E. de Vries, et al. · Journal of Clinical Oncology · 125
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
2021 · R.A. Soo, J.-Y. Han, et al. · Annals of Oncology · 108
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
2017 · Igor Letovanec, Stephen Finn, et al. · Journal of Thoracic Oncology · 84
PDF
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey
2018 · Susana Banerjee, Urania Dafni, et al. · ESMO Open · 80
PDF
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
2025 · N.I. Cherny, S.F. Oosting, et al. · Annals of Oncology · 75
PDF
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
2021 · B. Gyawali, E.G.E. de Vries, et al. · ESMO Open · 73
PDF
Report on the status of women occupying leadership roles in oncology
2018 · Eva Hofstädter-Thalmann, Urania Dafni, et al. · ESMO Open · 51
PDF
Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients
2018 · K. Homicsko, G. Richtig, et al. · Annals of Oncology · 38
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
2023 · B. Kiesewetter, U. Dafni, et al. · Annals of Oncology · 37
PDF
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
2019 · Erik Thunnissen, Keith M. Kerr, et al. · Modern Pathology · 32
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines
2022 · G. Zarkavelis, A.L. Amylidi, et al. · ESMO Open · 25
European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database
2023 · Isabelle Opitz, Andrea Bille, et al. · Journal of Thoracic Oncology · 21
PDF
EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
2020 · Barbara Kiesewetter, Nathan I. Cherny, et al. · ESMO Open · 19
PDF
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
2023 · Krisztian Homicsko, Panagiota Zygoura, et al. · Journal for ImmunoTherapy of Cancer · 18
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
2022 · U. Dafni, R.A. Soo, et al. · ESMO Open · 14
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
2020 · Daan Geert Knapen, Nathan I. Cherny, et al. · ESMO Open · 10
PDF
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort
2018 · Undine Rulle, Zoi Tsourti, et al. · Journal of Thoracic Oncology · 7
PDF
Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients with Resectable NSCLC: Still an Open Question. Comments on Marinelli et al. J Thorac Oncol. 2025;20:285–295
2025 · Urania Dafni, Zoi Tsourti, et al. · Journal of Thoracic Oncology · 6
Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period
2022 · C. Lazor-Blanchet, P. Zygoura, et al. · Journal of Infection · 6
PDF
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial
2022 · Giuseppe Luigi Banna, Alfredo Addeo, et al. · Lung Cancer · 5
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project
2025 · Martina Haberecker, Jan H. Rüschoff, et al. · JCO Precision Oncology · 3
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
2022 · Jan Hendrik Rüschoff, Martina Haberecker, et al. · Modern Pathology · 2
PDF
“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
2022 · N.I. Cherny, U. Dafni, et al. · ESMO Open · 1
PDF
Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
2026 · Ross A Soo, Sanjay Popat, et al. · The Lancet Respiratory Medicine
Works count: 29
Citation count: 1,053
H-index: 16
I10-index: 18
Year
Topic
Type